Secondary Cardiovascular Prevention Post-acute Myocardial Infarction (AMI) Through a Web-based Empowerment Program
- Disease/Condition
- Acute Myocardial Infarction
- Drug/Device/Intervention
- Digital empowerment
- Study type
- Interventional
- Intervention type
- behavioral
- Primary sponsor
- Centro Cardiologico Monzino
- Location
- Milan, Italy
- Phase
- N/A
- Start date
- Oct 18, 2022
- End date
- Sep 01, 2025
- Enrollment
- 400 participants
Efficacy on measurable risk factors - BMI,Efficacy on measurable risk factors - systolic blood pressure,Efficacy on measurable risk factors - diastolic blood pressure,Efficacy on measurable risk factors - LDL-cholesterol levels,Efficacy on measurable risk factors - glycemia levels,Efficacy on measurable risk factors - glycosylated hemoglobin in diabetic patients,Efficacy on measurable risk factors - expired carbon monoxide in smokers
The aim of this study is to assess the efficacy of an innovative program of secondary
 cardiovascular prevention focused on patient empowerment. This program will be characterized
 by a blended interaction between healthcare workers and the patients: first, a face-to-face
 first encounter in-hospital for risk factors profiling, followed by remote interactions
 through a digital approach. The digital intervention is targeted at promoting the adoption
 and retention of virtuous behavior (e.g. smoking cessation, healthy eating habits, physical
 exercise, regular assumption of pharmacological therapies), improving cardiovascular risk
 factors control. Moreover, an exploratory endpoint will be investigated: the reduction of the
 residual coronary risk.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05782023
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05782023 through Pure Global AI's free database. This phase not specified trial is sponsored by Centro Cardiologico Monzino and is currently Recruiting. The study focuses on Acute Myocardial Infarction. Target enrollment is 400 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.